From: A survey of population-based utility scores for cervical cancer prevention
Health state | Age groups | Wilcoxan rank sum test P value | |||
---|---|---|---|---|---|
20-49 years | 50-69 years | ||||
Mean utility score | Median utility score (IQR) | Mean utility score | Median utility score | ||
(SE) | (SE) | (IQR) | |||
Cytology normal | 0.9938 | 0.9997 | 0.9990 | 0.9999 | 0.4932 |
(0.0055) | (0.9994 - 1.0) | (0.0004) | (0.9994 - 1.0) | ||
HPV vaccination | 0.9992 | 0.9998 | 0.9539 | 1.0 | 0.6534 |
( 0.0004) | (0.9994 - 1.0) | ( 0.0454) | (0.9996 - 1.0) | ||
LG cytology | 0.9935 | 0.9997 | 0.9563 | 0.9998 | 0.2855 |
(0.0055) | (0.9993 - 0.9999) | (0.0429) | (0.9996 - 1.0) | ||
LG cytology with colposcopy normal | 0.9909 | 0.9997 | 0.9563 | 0.9997 | 0.3383 |
(0.0070) | (0.9950 - 0.9999) | (0.0420) | (0.9969 - 1.0) | ||
HPV positive with cytology normal | 0.9942 | 0.9997 | 0.9552 | 0.9997 | 0.3379 |
(0.003955) | (0.9959 - 0.9999) | ( 0.0434) | (0.9977 - 1.0) | ||
HPV positive with colposcopy normal | 0.9934 | 0.9997 | 0.9990 | 0.9998 | 0.1280 |
( 0.0045) | (0.9950 - 0.9999) | (0.0004) | (0.9989 - 0.9999) | ||
Treated genital warts | 0.9894 | 0.9997 | 0.9532 | 0.9997 | 0.2483 |
( 0.0056) | (0.9950 - 0.9999) | ( 0.0454) | (0.9990 - 1.0) | ||
HG cytology with CIN 1 | 0.9956 | 0.9997 | 0.9523 | 0.9996 | 0.3725 |
( 0.0024) | (0.9950 - 0.9997) | (0.0420) | (0.9977 - 0.9999) | ||
HG cytology with CIN 2 or 3 | 0.9908 | 0.9995 | 0.9527 | 0.9996 | 0.2826 |
(0.0049) | (0.9948 - 0.9997) | (0.0433) | (0.9983 - 1.0) | ||
Early stage cervical cancer | 0.7977 | 0.9450 | 0.8352 | 0.960 | 0.2616 |
(0.0819) | (0.8850 - 0.9750) | (0.0709) | (0.915 - 0.995) |